BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/21/2025 7:06:13 AM | Browse: 6 | Download: 30
 |
Received |
|
2025-07-28 04:47 |
|
Peer-Review Started |
|
2025-07-28 04:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-08-19 09:12 |
|
Revised |
|
2025-08-29 02:54 |
|
Second Decision |
|
2025-10-20 02:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-10-21 02:36 |
|
Articles in Press |
|
2025-10-21 02:36 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-10-26 19:45 |
|
Typeset the Manuscript |
|
2025-11-14 09:01 |
|
Publish the Manuscript Online |
|
2025-11-21 07:06 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Breaking through the transarterial chemoembolization resistance barrier: Reshaping the treatment path for advanced liver cancer with triple therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Su-Ming Shi, Qing-Qing Zhou, Yi-Meng Ren and Teng-Fei Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82404058 |
| Shanghai Municipal Commission of Health and Family Planning |
No. 2024ZZ2049 |
| Beijing Xisike Clinical Oncology Research Foundation |
No. Y-HS202401-0011 |
|
| Corresponding Author |
Teng-Fei Liu, PhD, Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 Huaihai West Road, Shanghai 200030, China. liutfei@alumni.sjtu.edu.cn |
| Key Words |
Transarterial chemoembolization resistance; Immune checkpoint inhibitors; Molecular targeted therapy; Hepatocellular carcinoma; Comment |
| Core Tip |
This article discusses a research article published recently, focusing on the synergistic value of triple therapy of transarterial chemoembolization combined with programmed death protein-ligand 1 inhibitors and molecular targeted therapy to overcome transarterial chemoembolization resistance in advanced liver cancer. The article covers relevant topics, and provides some insights into the application of the triple therapy in clinical practice. |
| Publish Date |
2025-11-21 07:06 |
| Citation |
<p>Shi SM, Zhou QQ, Ren YM, Liu TF. Breaking through the transarterial chemoembolization resistance barrier: Reshaping the treatment path for advanced liver cancer with triple therapy. <i>World J Clin Oncol</i> 2025; 16(11): 112404</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i11/112404.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i11.112404 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
